EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era

James R Janopaul-Naylor, Yichun Cao, Neal S McCall, Jeffrey M Switchenko, Sibo Tian, Haijian Chen, William A Stokes, Aparna H Kesarwala, Mark W McDonald, Joseph W Shelton, Jeffrey D Bradley, Kristin A Higgins

Frontiers in Oncology · 17.01.2023 · 12

DOI: 10.3389/fonc.2022.1074675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 17.01.2023. Verfasst von James R Janopaul-Naylor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Winship Cancer Institute, Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, United States. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

As immunotherapy has improved distant metastasis-free survival (DMFS) in Non-Small Cell Lung Cancer (NSCLC), isolated locoregional recurrences have increased. However, management of locoregional recurrences can be challenging. We report our institutional experience with definitive intent re-irradiation using Intensity Modulated Proton Therapy (IMPT).

Method

Retrospective cohort study of recurrent or second primary NSCLC or LS-SCLC treated with IMPT. Kaplan-Meier method and log-rank test were used for time-to-event analyses.

Results

22 patients were treated from 2019 to 2021. After first course of radiation (median 60 Gy, range 45-70 Gy), 45% received adjuvant immunotherapy. IMPT re-irradiation began a median of 28.2 months (8.8-172.9 months) after initial radiotherapy. The median IMPT dose was 60 GyE (44-60 GyE). 36% received concurrent chemotherapy with IMPT and 18% received immunotherapy after IMPT. The median patient’s IMPT lung mean dose was 5.3 GyE (0.9-13.9 GyE) and 5 patients had cumulative esophagus max dose >100 GyE with 1-year overall survival (OS) 68%, 1-year local control 80%, 1-year progression free survival 45%, and 1-year DMFS 60%. Higher IMPT (HR 1.4; 95% CI 1.1-1.7, p=0.01) and initial radiotherapy mean lung doses (HR 1.3; 95% CI 1.0-1.6, p=0.04) were associated with worse OS. Two patients developed Grade 3 pneumonitis or dermatitis, one patient developed Grade 2 pneumonitis, and seven patients developed Grade 1 toxicity. There were no Grade 4 or 5 toxicities.

Discussion

Definitive IMPT re-irradiation for lung cancer can prolong disease control with limited toxicity, particularly in the immunotherapy era.

Schlagwörter

Stichwörter der Autor:innen

bronchial necrosisimmunotherapylung cancerproton therapyradiation dermatitisre-irradiation

Autor:innen und Institutionen

  • Winship Cancer Institute, Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, United States.
  • Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA, United States.
  • Rollins School of Public Health, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, United States.

Förderung

  • NCI NIH HHS

Zitieren

APA

Janopaul-Naylor, J. R., Cao, Y., McCall, N. S., Switchenko, J. M., Tian, S., Chen, H., Stokes, W. A., Kesarwala, A. H., McDonald, M. W., Shelton, J. W., Bradley, J. D., & Higgins, K. A. (2023). Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1074675

Vancouver

Janopaul-Naylor JR, Cao Y, McCall NS, Switchenko JM, Tian S, Chen H, et al. Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era. Frontiers in Oncology. 2023;12. doi:10.3389/fonc.2022.1074675

BibTeX
@article{JanopaulNaylor2023,
  author = {Janopaul-Naylor, James R and Cao, Yichun and McCall, Neal S and Switchenko, Jeffrey M and Tian, Sibo and Chen, Haijian and Stokes, William A and Kesarwala, Aparna H and McDonald, Mark W and Shelton, Joseph W and Bradley, Jeffrey D and Higgins, Kristin A},
  title = {Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {12},
  doi = {10.3389/fonc.2022.1074675}
}
Kostenlos starten →